Cartesian Therapeutics Inc (RNAC) Stock Price, Quote & News

Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile derma...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 348 8698

Website: www.cartesiantherapeutics.com

Address:

7495 New Horizon Way, Frederick, United States

doDD22 Nov. 15 at 2:38 PM

$RNAC I wouldn’t necessarily count them out Springer is interested in buyouts But that won’t happen until 20+ which may take some time Or drug approval I no longer have a position Just selb cvrs Left because I didn’t want to dig into new trial But from what I remember rnac does have some production capabilities which could prove to be valuable

0 · Reply

JarvisFlow Nov. 14 at 1:11 PM

BTIG updates rating for Cartesian Therapeutics ( $RNAC ) to Buy, target set at 42 → 44.

0 · Reply

4976f2e Nov. 13 at 9:25 PM

$RNAC Interesting https://www.globenewswire.com/news-release/2025/11/13/3187838/0/en/Cartesian-Therapeutics-Announces-Strong-Efficacy-Signal-in-Phase-2-Trial-of-Descartes-08-in-Patients-with-SLE-and-Expansion-of-Clinical-Development-into-Myositis.html

0 · Reply

StockFactz Nov. 13 at 6:43 PM

$RNAC What the f*ck is wrong with this company, might just sell here at a 10% loss

1 · Reply

EmbryonicJourney Nov. 12 at 5:26 PM

$RNAC Looking at the YTD graph is just depressing. Can someone remind me, how come we went from $20 to $10 in 3 months at the start of the year

1 · Reply

StockFactz Nov. 11 at 6:42 PM

$RNAC All bio tech stocks ripping today and this shit is barely up 😂 what is this company doing

0 · Reply

kimgysen Nov. 10 at 9:24 PM

$RNAC Probably lost 10$ at this point

0 · Reply

ThomasTrainTrader Nov. 10 at 8:40 PM

$RNAC I’m down 20% in 1 month which is crazy considering I bought already near all time lows 🤣, crazy stuff you never know how the market will play out, stay safe out there boys I’m still holding still with a first target of around $14

0 · Reply

doDD22 Nov. 10 at 6:11 PM

$RNAC so happy they spun off the CVR for old SELB don't need to worry about new RNAC

0 · Reply

KarlWolf Nov. 7 at 8:48 PM

$RNAC what can i do with this ?

0 · Reply

Cartesian Therapeutics Announces New Employment Inducement Grants

Oct 3, 2025, 7:05 AM EDT - 6 weeks ago

Cartesian Therapeutics Announces New Employment Inducement Grant

Sep 9, 2025, 7:09 PM EDT - 2 months ago

Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

May 30, 2025, 7:00 AM EDT - 6 months ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 8, 2025, 7:00 AM EDT - 6 months ago

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 8, 2025, 7:00 AM EDT - 7 months ago

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Jan 27, 2025, 7:00 AM EST - 10 months ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Dec 3, 2024, 6:00 AM EST - 1 year ago

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Nov 21, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Nov 10, 2024, 12:26 PM EST - 1 year ago

Cartesian Therapeutics: Uncertainty Remains

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Sep 17, 2024, 9:45 AM EDT - 1 year ago

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Jul 2, 2024, 12:55 PM EDT - 1 year ago

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Jul 2, 2024, 6:40 AM EDT - 1 year ago

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Jul 2, 2024, 6:30 AM EDT - 1 year ago

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

May 22, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

May 13, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 8, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Mar 7, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

doDD22 Nov. 15 at 2:38 PM

0 · Reply

JarvisFlow Nov. 14 at 1:11 PM

BTIG updates rating for Cartesian Therapeutics ( $RNAC ) to Buy, target set at 42 → 44.

0 · Reply

4976f2e Nov. 13 at 9:25 PM

0 · Reply

StockFactz Nov. 13 at 6:43 PM

$RNAC What the f*ck is wrong with this company, might just sell here at a 10% loss

1 · Reply

EmbryonicJourney Nov. 12 at 5:26 PM

$RNAC Looking at the YTD graph is just depressing. Can someone remind me, how come we went from $20 to $10 in 3 months at the start of the year

1 · Reply

StockFactz Nov. 11 at 6:42 PM

$RNAC All bio tech stocks ripping today and this shit is barely up 😂 what is this company doing

0 · Reply

kimgysen Nov. 10 at 9:24 PM

$RNAC Probably lost 10$ at this point

0 · Reply

ThomasTrainTrader Nov. 10 at 8:40 PM

0 · Reply

doDD22 Nov. 10 at 6:11 PM

$RNAC so happy they spun off the CVR for old SELB don't need to worry about new RNAC

0 · Reply

KarlWolf Nov. 7 at 8:48 PM

$RNAC what can i do with this ?

0 · Reply

Bobsmitt333 Nov. 7 at 10:37 AM

$RNAC Sooo close to 90 million burn rate per year and 145 million left, they are not going to run the tank dry before another offering, more dilution coming soon.

0 · Reply

50shadesoftrades Nov. 6 at 7:25 PM

$MTC $RNAC $WORX $URGN $EZGO Intraday gainers https://go.trade-ideas.com/SH14L

0 · Reply

abcdzepeda Nov. 5 at 8:32 PM

$RNAC at this price, why isn’t Springer buying more shares?

0 · Reply

ThomasTrainTrader Nov. 5 at 4:39 PM

$RNAC bro -40% in 3 months on top of already being down -45% for the year before that?

0 · Reply

ThomasTrainTrader Nov. 4 at 8:16 PM

$RNAC it’s insane that $MGX is up 10% in the last year and this shit is down 60%. A company with essentially 0 viable assets has a +70% delta on a stock that has a best in class asset

0 · Reply

ThomasTrainTrader Nov. 4 at 7:52 PM

$RNAC I think it would be pretty foolish to solely blame management with the current headwinds biotech is facing but it’s also funny how bad of a track record Carsten Brunn has had delivering share holder returns in the last 5 years while also taking a massive salary, reduce your salary until the product launches Carsten! Or at least unless you can secure more funding 🤣

1 · Reply

ThomasTrainTrader Nov. 4 at 7:48 PM

$RNAC Based on technicals and fundamentals this belongs around $12-14 region. But seems like there is no interest at all to buy at the moment. Seems most likely to just be macro economic conditions combined with a string of bad luck for the stock.

0 · Reply

ThomasTrainTrader Nov. 4 at 7:45 PM

$RNAC Chant it with me! 52 Week Lows! This is actually pretty insane though but it makes more sense considering how thinly traded this is

0 · Reply

YOLOartist Nov. 4 at 6:44 PM

$RNAC anybody got any bright ideas? 10 sure seemed like the floor, and now we’ve just blown past 8!? Never thought it could possibly get this bad.

2 · Reply

ThomasTrainTrader Nov. 4 at 6:19 PM

$RNAC added, now I’m at 35K shares this is my full position

0 · Reply

kimgysen Nov. 4 at 3:06 PM

$RNAC History of SELB in a nushell: 4, 5 -> RS -> RNAC = SELB -> 20 -> 15 -> 10 -> 9 -> 8 -> 7

1 · Reply

ThomasTrainTrader Nov. 3 at 8:50 PM

$RNAC it feels like it has not moved from this exact price for a million years at this point

1 · Reply

Market Cap	193.99M
Revenue (ttm)	38.91M
Net Income (ttm)	-77.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-198.97%
Debt to Equity Ratio	0.00

Volume	96,900
Avg Vol	110,618
Day's Range	N/A - N/A
Shares Out	26.00M
Stochastic %K	68%
Beta	0.44
Analysts	Strong Sell
Price Target	$36.43